drsue.ca
Does The World’s First Oral GLP1 Receptor Agonist Reduce Cardiovascular Events? - Dr Sue
In the treatment of type 2 diabetes, one of our goals is to prevent cardiovascular events such as heart attacks and stroke. In the development of new diabetes medications, it is required by the FDA that medications are proven to be safe from a cardiovascular risk perspective – and if they can show cardiovascular benefit, …